A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea-Reference-Cited by-同舟云学术

A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea

Published:2023 Issue:32 Volume:38 Page:
ISSN:1011-8934
Container-title:Journal of Korean Medical Science
language:en
Short-container-title:J Korean Med Sci

Author:

Jo Youngji¹^ORCID,Kim Sun Bean²^ORCID,Jung Jaehun³⁴^ORCID

Affiliation:

1. Department of Public Health Sciences, School of Medicine, University of Connecticut, Farmington, CT, USA.

2. Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.

3. Artificial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.

4. Department of Preventive Medicine, Gachon University College of Medicine, Incheon, Korea.

Funder

National Research Foundation of Korea

Ministry of Science and ICT, South Korea

Ministry of Health and Welfare

Publisher

XMLink

Subject

General Medicine

Link

https://jkms.org/pdf/10.3346/jkms.2023.38.e250

Reference38 articles.

1. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies

2. Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic

3. Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

4. Food and Drug Administration (US). FDA authorizes revisions to Evusheld dosing. Updated 2022. Accessed September 20, 2022. https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-evusheld-dosing

5. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China;Emerging Microbes & Infections;2023-11-16